Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

BACKGROUND: Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and the prediction of individual limiting toxicity syndr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ther Adv Med Oncol
Prif Awduron: Bruera, Gemma, Massacese, Silvia, Pepe, Francesco, Malapelle, Umberto, Dal Mas, Antonella, Ciacco, Eugenio, Calvisi, Giuseppe, Troncone, Giancarlo, Simmaco, Maurizio, Ricevuto, Enrico
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: SAGE Publications 2019
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535746/
https://ncbi.nlm.nih.gov/pubmed/31205502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919846421
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg